The Source-Omega company raised criticism that “The Institute of Medicine has now allegedly been wrong three times with respect to the 41-year history of data on marine long-chain omega-3 fatty acid knowledge and associated claims made based on fundamental misinterpretations of the data that have always been there,” alleged and claimed Scott Doughman, PhD, CEO and chief scientific officer at Source-Omega. Dr Doughman is a former National Institutes of Health funded omega-3 researcher and indicated the company's three years of work on a "Review in Submission" shows their references for the omega-3 lipidology Doughman publishes.
Based on Dr Doughman’s research, the Source-Omega company has become concerned with IOM authority with respect to the following scientific history:
1) Eskimo studies showed intestinal lipoprotein concentrations inversely correlated with DHA/EPA intake, suggesting postprandial benefits from an omega-3 DHA/EPA-rich diet, which reduced dietary blood fat concentrations and the risk of type 2 diabetes. Heart health was a benefit interpreted from these data, not demonstrated. The potential reduced risk of type 2 diabetes onset has received little attention while remaining scientifically sound as a fundamental principle of science, not medicine.
2) The recommendation of statin use does not affect the postprandial state and the body's omega-3/omega-6 ratios are apparently negatively impacted by statin use. Statins do not improve morbidity and mortality and long chain omega-3 fatty acids do with regard to statistical long term use.
3) Tolerance for poorly conducted science as authoritative-by-committee regarding the historic type 2 diabetes warnings that emerged from 'The Menhaden Study,' without further review and with a potential lack of understanding of the merits of omega-3 science as now practiced compared to the same in the past, which medicines also lacked regarding the same high-tech analyses as conducted today; also silent when negative retrospective data is given reign in public as medically meritorious conclusions by licensed professionals, especially when related to omega-3 fatty acids in medical outcomes, as if the lack of good science is sufficiently acceptable as preliminary data to be then accessed for broad use made unreasonably authoritative by advertisement of a scientific opinion related to the practice of medicine and the historical omega-3 data.
The Source-Omega company also suggested the following with respect to implied up-to-date omega-3 knowledge:
7 Omega-3 Myths:
1) Medical doctors are trained omega-3 fatty acid experts.
2) Omega-3 fatty acids benefit disease conditions directly with drug specificity.
3) Krill phospholipids enter the brain and do not in fact get digested in the intestine as food.
4) Krill oil antioxidants are synergistic and not just natural oil-in-capsule preservatives.
5) EPA signaling takes place in circulating plasma before the EPA is incorporated into cells.
6) Overdose or lack of upper limit of omega-3 is real and dangerous.
7) Algae oil omega-3s are GMOs and tainted with solvents [false].
7 Omega-3 Truths
1) Eskimo studies showed intestinal lipoprotein concentrations inversely correlated with DHA/EPA intake, suggesting postprandial benefits from DHA-rich diets reduce dietary blood fat concentrations and risk of type 2 diabetes. Heart health was a benefit interpreted from this data, not demonstrated. Type 2 diabetes risk reduction was implicated in the Eskimo studies, but not further interpreted, even though it was arguably the only correct interpretation of that data.
2) DHA retroconversion in cells is robust, exothermic and coordinated by the body to give all the EPA the body needs, on demand.
3) Krill, squid and fish omega-3s ultimately came from algae omega-3s at the base of the marine food chain.
4) After 3 months of 1 gram EPA only or 1 gram DHA only, there is no difference in physiological tissue composition of omega-3 and relative omega-3 index outcome.
5) The body has about 80 percent DHA/20 percent EPA overall ratios of long chain omega-3s at all times.
6) Regular consumption of long chain omega-3s can double total blood cell omega-3 levels.
7) Long term regular consumption of DHA/EPA improves morbidity and mortality, statins do not.